Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Single-center, Cross-over Study in Healthy Subjects to Assess the Relative Bioavailability of EPA and DHA Delivered by Three New Capsule Formulation Prototypes in Relation to the Current Epanova® Capsule Under Fasting (Part 1) and Fed (Part 2) Conditions
Conditions
Interventions
D1400147
D14000136
+2 more
Locations
1
United States
Research Site
Baltimore, Maryland, United States
Start Date
February 12, 2015
Primary Completion Date
July 27, 2015
Completion Date
July 27, 2015
Last Updated
May 1, 2017
NCT04354545
NCT07298356
NCT05992532
NCT07396441
NCT06979752
NCT07390890
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions